Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of LCP-Tacro (tacrolimus) Tablets
administered once-a-day compared to Prograf (tacrolimus) Capsules twice-a-day as
immunosuppression for the prevention of organ rejection in newly transplanted adult kidney
transplant recipients. Patients will be treated for a 12 month study period followed by a 12
month, blinded extension treatment period To show that LCP-Tacro Tablets are clinically
similar to Prograf Capsules in the prevention of acute rejection.